Confronto
Goserelin vs. Linaclotid
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
65807-02-5
851199-59-2
Peso molecolare
1269.43 g/mol
1526.74 g/mol
Emivita
4.2 h
nessun dato
Sequenza
pGlu-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-Azgly-NH2nessun dato
Meccanismo d'azione
Goserelin
As a GnRH agonist, goserelin binds to the GnRH receptors of the pituitary gland. Initial stimulation transiently raises luteinizing hormone (LH) and follicle-stimulating hormone (FSH). With continuous receptor occupancy, however, the receptors become desensitized and down-regulated, which reduces LH and FSH secretion and consequently the production of testosterone or estrogen. This mechanistic relationship is documented in the pharmacological literature.
Linaclotid
Linaclotide activates the guanylate cyclase-C receptor on the luminal surface of the intestinal epithelium. This raises cyclic GMP (cGMP), increases secretion of chloride and bicarbonate into the lumen, raises stool fluid content and accelerates transit; pain signaling is also modulated.
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
4
0
di cui sull'uomo
4
0
Effetti registrati
3
2
Contraddizioni aperte
1
0
Eventi avversi documentati
2
1
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Goserelin and Linaclotid?
- Goserelin is classified as "Ricerca (altro)", while Linaclotid is classified as "Ricerca (altro)". Goserelin: Goserelin is a synthetic decapeptide and an agonist of gonadotropin-releasing hormone (GnRH). The medical literature describes it as a hormonal agent that suppresses the release of sex hormones through sustained receptor stimulation. Regulatory-approved indications include prostate cancer, advanced breast cancer, endometriosis, and endometrial thinning, among others. Linaclotid: Linaclotide is a 14-amino-acid peptide and guanylate cyclase-C (GC-C) agonist. It is approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Goserelin or Linaclotid?
- The highest available evidence level is "RCT sull'uomo" for Goserelin and "RCT sull'uomo" for Linaclotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Goserelin and Linaclotid in Germany and the United States?
- Germania: Goserelin — Su prescrizione, Linaclotid — Su prescrizione. Stati Uniti: Goserelin — Su prescrizione, Linaclotid — Su prescrizione. These are factual summaries with source and review date on the individual pages.